Correction: Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial (The Lancet Oncology (2017) 18(7) (895–903) (S1470204517303807) (10.1016/S1470-2045(17)30380-7));Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

The Lancet Oncology

Volumn 18, Issue 7, 2017, Pages 895-903

  Shaverdian, Narek ^a   Lisberg, Aaron E ^b   Bornazyan, Krikor ^b   Veruttipong, Darlene ^a   Goldman, Jonathan W ^b   Formenti, Silvia C ^c   Garon, Edward B ^b   Lee, Percy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT RESPONSE; UNITED STATES; ADVERSE EFFECTS; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LUNG DISEASES; LUNG NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RETREATMENT; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY; RETREATMENT; SURVIVAL RATE;

EID: 85019941130     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30409-6     Document Type: Erratum

References (28)

1. Siegel, RL, Miller, KD, Jemal, A, Cancer statistics, 2016. CA Cancer J Clin 66 (2016), 7–30.
2. Didkowska, J, Wojciechowska, U, Manczuk, M, Lobaszewski, J, Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Trans Med, 4, 2016, 150.
3. Garon, EB, Rizvi, NA, Hui, R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
4. Reck, M, Rodriguez-Abreu, D, Robinson, AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.
5. Gettinger, SN, Horn, L, Gandhi, L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, bms-936558, ono-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33 (2015), 2004–2012.
6. Herbst, RS, Baas, P, Kim, DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
7. Formenti, SC, Demaria, S, Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 84 (2012), 879–880.
8. Demaria, S, Golden, EB, Formenti, SC, Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 1 (2015), 1325–1332.
9. Reits, EA, Hodge, JW, Herberts, CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203 (2006), 1259–1271.
10. Sharabi, AB, Lim, M, DeWeese, TL, Drake, CG, Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16 (2015), e498–e509.
11. Sharabi, AB, Nirschl, CJ, Kochel, CM, et al. Stereotactic radiation therapy augments antigen-specific pd-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 3 (2015), 345–355.
12. Gupta, A, Probst, HC, Vuong, V, et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J Immunol 189 (2012), 558–566.
13. Liao, YP, Wang, CC, Butterfield, LH, et al. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol 173 (2004), 2462–2469.
14. Herter-Sprie, GS, Koyama, S, Korideck, H, et al. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight, 16, 2016, e87415.
15. Twyman-Saint Victor, C, Rech, AJ, Maity, A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377.
16. Sallusto, F, Lanzavecchia, A, Araki, K, Ahmed, R, From vaccines to memory and back. Immunity 33 (2010), 451–463.
17. Wolchok, JD, Hoos, A, S O'Day, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
18. Muldoon, LL, Alvarez, JI, Begley, DJ, et al. Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab 33 (2013), 13–21.
19. Pachter, JS, de Vries, HE, Fabry, Z, The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 62 (2003), 593–604.
20. Lin, DY, Wei, LJ, Ying, Z, Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 80 (1993), 557–572.
21. Vanpouille-Box, C, Pilones, KA, Wennerberg, E, Formenti, SC, Demaria, S, In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine 33 (2015), 7415–7422.
22. Larmonier, N, Merino, D, Nicolas, A, et al. Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. Apoptosis 11 (2006), 1513–1524.
23. Lugade, AA, Moran, JP, Gerber, SA, Rose, RC, Frelinger, JG, Lord, EM, Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174 (2005), 7516–7523.
24. Schaue, D, Comin-Anduix, B, Ribas, A, et al. T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res 14 (2008), 4883–4890.
25. Tang, C, Wang, X, Soh, H, et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors?. Cancer Immunol Res 2 (2014), 831–838.
26. Martinov, T, Fife, BT, Fractionated radiotherapy combined with PD-1 pathway blockade promotes CD8 T cell-mediated tumor clearance for the treatment of advanced malignancies. Ann Transl Med, 4, 2016, 82.
27. Nishino, M, Giobbie-Hurder, A, Hatabu, H, Ramaiya, NH, Hodi, FS, Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2 (2016), 1607–1616.
28. Kang, J, Demaria, S, Formenti, S, Current clinical trials testing the combination of immunotherapy with radiotherapy. J ImmunoTherapy Cancer, 4, 2016, 51.